RESEARCH TRIANGLE PARK, N.C., June 17 /PRNewswire/ -- Amphora Discovery
Corporation, a newly created chemical genomics company, announced today the
addition of two key members to its management team. Cesar R. Collado joins as
Vice President of Business Development and Commercialization and Holly M.
Marcum joins as Executive Director of Business Development and
Commercialization. Mr. Collado and Ms. Marcum each have significant business
development experience in the pharmaceutical and biotechnology industries and
will be responsible for commercial development activities at Amphora
Discovery.
"We are excited to have Cesar and Holly leading our business development
and commercialization efforts at Amphora. Cesar brings significant breadth
and experience doing strategic transactions for Eli Lilly & Co., and Holly has
extensive business development experience in biotechnology and life sciences.
Each of them bring a wealth of capability in deal making and strategy to
Amphora and will be instrumental as we identify and enter into strategic
relationships with other biotechnology and pharmaceutical companies," says
Marty Haslanger, President and CEO of Amphora Discovery Corporation. "Cesar
and Holly bring complementary experiences and skill sets which will enable
Amphora to fully leverage our technologies for strategic value creation."
Mr. Collado has 12 years of experience in the pharmaceutical industry,
eight of which were spent in various capacities in Corporate Strategy and
Business Development group at Eli Lilly & Co. Cesar has successfully
negotiated numerous partnerships of varying complexities spanning the value
chain from discovery to commercialization. In addition to his transaction
experience, Mr. Collado has participated in numerous strategic and licensing
process initiatives and has also had responsibility for the implementation of
several strategic partnerships at Lilly. Mr. Collado received his B.A. in
Business Management from the University of New Mexico and his MBA from Duke
University's Fuqua School of Business.
Ms. Marcum has over ten years of experience in the biotechnology and life
science industries in positions of increased responsibility in corporate
business development and sales and marketing. Most recently, Ms. Marcum was
Senior Director of Corporate Development for Incyte Genomics, where she
negotiated, structured and implemented numerous strategic partnerships with
companies utilizing Incyte's gene information and intellectual property for
commercial purposes. Prior to Incyte, Ms. Marcum held various key positions
in business development and sales and marketing at Perkin Elmer Life Sciences
Corporation and Life Technologies, Inc. Ms. Marcum received her B.A. in
Molecular Biology from Middlebury College and is currently completing her MBA
at Duke University's Fuqua School of Business.
Amphora Discovery Corp. is a newly-formed drug discovery company whose aim
is to improve the drug discovery and development process and generate high
quality drug candidates across important classes of therapeutic targets.
Amphora is leveraging its know-how and exclusive technology rights in
microfluidics to generate and commercialize a knowledge base of chemical
genomics information of unprecedented quality and scale. The chemical
genomics knowledge base, which will detail the interactions of small molecules
against a broad array of biological targets, will include data on potency,
specificity, drug absorption, metabolism, toxicology and physical properties
of individual molecules. The information will be instrumental in preclinical
drug discovery, acceleration of target validation, lead identification and
medicinal chemistry, as well as in increasing the success rate of drugs
through clinical development. Utilization of information of this quality and
breadth will revolutionize the drug discovery process, shortening the period
from biology discovery to useful medicine and enabling the development of
better drugs, faster and more economically.
Amphora plans to provide this information on a strategic and collaborative
basis directly to pharmaceutical and biotechnology companies involved in
preclinical and clinical research in life sciences. Amphora anticipates
industrializing screening on an unprecedented scale, not previously
contemplated, utilizing Caliper Technologies Corp.'s LabChip high throughput
screening systems to create, build and expand its chemical genomics Knowledge
Sets. Amphora has the exclusive rights from Caliper to utilize this enabling
technology for these purposes.
For more information about Amphora, please see our website at
http://www.amphoracorp.com. LabChip is a registered trademark of Caliper
Technologies Corp.
Contact: Cesar Collado
Amphora Discovery Corporation
VP Business Development & Commercialization
PO Box 12169
Research Triangle Park, NC 27709
919.287.6214
SOURCE Amphora Discovery Corporation
 back to top
Related links:
http://www.amphoracorp.com
CONTACT:
Cesar Collado, VP Business Development &
Commercialization of Amphora Discovery Corporation,
+1-919-287-6214
|
